My goodness what a financial drain this is. Fortunately my dad had plenty of assets, income, and a really good LTC policy.
I would be interested in hearing from the good doctor, DisneySteve, as to how you see this affecting families that come to you. How they manage it all.
Also, are there any drugs/therapies that you see on the horizon? The one that looks promising that is in Phase 3 is aducanumab from Biogen.
I hate to get too hopeful because of all of the Phase 3 heartbreaks we've had over the last 15 years.
What really makes me optimistic about aducanumab is that Biogen has been negotiating very hard with Neurimmune, the company that originated aducanumab, regarding royalty payments on the drug if/when it goes to market: Apparently, Biogen has negotiated a $50 million one-time payment to Neurimmune, in addition to paying Neurimmune a royalty on sales of 10 percent +/-. This is the second time in a year that Biogen and Neurimmune have renegotiated.
That tells me that the folks at Biogen feel like they may have a big one on their hands and that Phase 3 is going well. But again it's hard to get too hopeful.
There is also talk that this drug could cost patients as much as $25,000 a year for the rest of their lives, so there's a lot to this from an economics standpoint, too.
Steve, what are your thoughts about the present and future on the Alzheimer's front, both the patient care and economic concerns sides?
I would be interested in hearing from the good doctor, DisneySteve, as to how you see this affecting families that come to you. How they manage it all.
Also, are there any drugs/therapies that you see on the horizon? The one that looks promising that is in Phase 3 is aducanumab from Biogen.
I hate to get too hopeful because of all of the Phase 3 heartbreaks we've had over the last 15 years.
What really makes me optimistic about aducanumab is that Biogen has been negotiating very hard with Neurimmune, the company that originated aducanumab, regarding royalty payments on the drug if/when it goes to market: Apparently, Biogen has negotiated a $50 million one-time payment to Neurimmune, in addition to paying Neurimmune a royalty on sales of 10 percent +/-. This is the second time in a year that Biogen and Neurimmune have renegotiated.
That tells me that the folks at Biogen feel like they may have a big one on their hands and that Phase 3 is going well. But again it's hard to get too hopeful.
There is also talk that this drug could cost patients as much as $25,000 a year for the rest of their lives, so there's a lot to this from an economics standpoint, too.
Steve, what are your thoughts about the present and future on the Alzheimer's front, both the patient care and economic concerns sides?
Comment